JENBURKT PHARMACEUTICALS
|
JENBURKT PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 58.86 | 55.76 | 48.58 | 35.96 | 32.40 |
| CEPS(Rs) | 64.16 | 60.88 | 52.72 | 40.39 | 37.41 |
| DPS(Rs) | 15.30 | 14.40 | 12.00 | 10.20 | 8.10 |
| Book NAV/Share(Rs) | 328.42 | 277.32 | 255.77 | 214.55 | 174.32 |
| Tax Rate(%) | 26.15 | 25.13 | 25.35 | 23.75 | 29.65 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 23.33 | 22.21 | 21.98 | 18.15 | 16.61 |
| EBIT Margin(%) | 24.97 | 24.30 | 24.44 | 20.23 | 18.22 |
| Pre Tax Margin(%) | 24.78 | 24.03 | 24.09 | 19.80 | 17.78 |
| PAT Margin (%) | 18.30 | 17.99 | 17.98 | 15.10 | 12.51 |
| Cash Profit Margin (%) | 19.95 | 19.65 | 19.52 | 16.96 | 14.44 |
| Performance Ratios | |||||
| ROA(%) | 17.00 | 17.33 | 16.95 | 14.68 | 14.37 |
| ROE(%) | 19.43 | 20.53 | 20.66 | 18.49 | 18.89 |
| ROCE(%) | 26.28 | 26.80 | 26.89 | 23.83 | 25.73 |
| Asset Turnover(x) | 0.93 | 0.96 | 0.94 | 0.97 | 1.15 |
| Sales/Fixed Asset(x) | 4.18 | 4.05 | 3.79 | 3.45 | 4.09 |
| Working Capital/Sales(x) | 1.52 | 2.09 | 2.27 | 1.76 | 1.70 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.24 | 0.25 | 0.26 | 0.29 | 0.24 |
| Receivable days | 46.84 | 42.93 | 42.99 | 53.15 | 62.51 |
| Inventory Days | 21.72 | 24.32 | 25.71 | 30.86 | 31.82 |
| Payable days | 84.76 | 84.44 | 77.81 | 64.63 | 71.48 |
| Valuation Parameters | |||||
| PER(x) | 11.71 | 11.94 | 11.66 | 11.08 | 9.81 |
| PCE(x) | 10.75 | 10.94 | 10.75 | 9.86 | 8.50 |
| Price/Book(x) | 2.10 | 2.40 | 2.22 | 1.86 | 1.82 |
| Yield(%) | 2.22 | 2.16 | 2.12 | 2.56 | 2.55 |
| EV/Net Sales(x) | 1.59 | 1.77 | 1.75 | 1.19 | 0.77 |
| EV/Core EBITDA(x) | 5.96 | 6.83 | 6.73 | 5.38 | 3.82 |
| EV/EBIT(x) | 6.35 | 7.30 | 7.16 | 5.88 | 4.23 |
| EV/CE(x) | 1.55 | 1.94 | 1.52 | 1.08 | 0.88 |
| M Cap / Sales | 2.14 | 2.15 | 2.10 | 1.67 | 1.23 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 3.82 | 10.30 | 13.44 | -8.07 | -3.06 |
| Core EBITDA Growth(%) | 6.47 | 10.21 | 33.35 | 0.78 | -15.54 |
| EBIT Growth(%) | 6.66 | 9.66 | 37.03 | 2.09 | -19.82 |
| PAT Growth(%) | 5.57 | 10.36 | 35.11 | 10.98 | -24.89 |
| EPS Growth(%) | 5.57 | 14.76 | 35.11 | 10.98 | -24.89 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.02 | 0.05 | 0.04 | 0.04 |
| Current Ratio(x) | 6.70 | 5.14 | 3.57 | 4.45 | 4.51 |
| Quick Ratio(x) | 6.18 | 4.62 | 3.10 | 4.02 | 3.96 |
| Interest Cover(x) | 130.99 | 90.55 | 69.76 | 46.69 | 41.22 |
| Total Debt/Mcap(x) | - | 0.01 | 0.02 | 0.02 | 0.02 |
Compare Financial Ratios of peers of JENBURKT PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| JENBURKT PHARMACEUTICALS | ₹496.8 Cr | 0.5% | 8.6% | 75% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,518.0 Cr | -0.1% | -6.3% | 49.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹158,636.0 Cr | 3.5% | 0.9% | 66.2% | Stock Analytics | |
| CIPLA | ₹118,368.0 Cr | -2.6% | -3.8% | 19.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,671.4 Cr | -4.1% | -10.8% | 9.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,013.6 Cr | -2% | -6.1% | 49.9% | Stock Analytics | |
JENBURKT PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JENBURKT PHARMACEUTICALS | 0.5% |
8.6% |
75% |
| SENSEX | -1.9% |
-5% |
17.5% |
You may also like the below Video Courses
